Werewolf Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Werewolf Therapeutics
HOWL Stock  USD 0.61  0.03  4.69%   
Werewolf Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Werewolf Therapeutics' valuation are provided below:
Gross Profit
-50.5 M
Market Capitalization
31.1 M
Enterprise Value Revenue
0.6742
Earnings Share
(1.57)
Quarterly Revenue Growth
(1.00)
There are over one hundred nineteen available fundamental gauges for Werewolf Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to confirm Werewolf Therapeutics' prevalent fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 70.1 M. Enterprise Value is expected to rise to about (10.7 M) this year

Werewolf Therapeutics Total Revenue

2.06 Million

Check Werewolf Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Werewolf Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 1.5 M, Depreciation And Amortization of 1.1 M or Interest Expense of 5.6 M, as well as many indicators such as Price To Sales Ratio of 32.15, Dividend Yield of 0.0 or PTB Ratio of 0.95. Werewolf financial statements analysis is a perfect complement when working with Werewolf Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Werewolf Stock
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.

Werewolf Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets139.2 M146 M72.9 M
Slightly volatile
Short and Long Term Debt Total22.9 M42.7 M12.9 M
Slightly volatile
Other Current Liabilities8.6 M12.2 M4.4 M
Slightly volatile
Total Current Liabilities14.3 M17.5 M7.5 M
Slightly volatile
Total Stockholder Equity102.5 M84.4 M49 M
Slightly volatile
Other Liabilities26.5 K27.9 K4.3 M
Slightly volatile
Property Plant And Equipment Net12.4 M14.2 M7.3 M
Slightly volatile
Accounts Payable3.7 M3.5 M1.3 M
Slightly volatile
Cash117.8 M127.6 M61.7 M
Slightly volatile
Non Current Assets Total17.5 M15.9 M9.5 M
Slightly volatile
Non Currrent Assets Other349.6 K368 K430 K
Slightly volatile
Other Assets1.091.15893.2 K
Pretty Stable
Cash And Short Term Investments117.8 M127.6 M61.7 M
Slightly volatile
Common Stock Total Equity2.5 K3.5 K2.3 K
Slightly volatile
Common Stock Shares Outstanding33.8 M50.4 M31 M
Slightly volatile
Liabilities And Stockholders Equity139.2 M146 M72.9 M
Slightly volatile
Non Current Liabilities Total22.5 M44.1 M16.4 M
Slightly volatile
Capital Lease Obligations10.9 M12.6 M6.6 M
Slightly volatile
Other Current Assets2.3 M2.4 M1.1 M
Slightly volatile
Other Stockholder Equity326 M561.2 M156.8 M
Slightly volatile
Total Liabilities36.8 M61.6 M23.9 M
Slightly volatile
Property Plant And Equipment Gross20.9 M19.9 M7.4 M
Slightly volatile
Total Current Assets121.7 M130 M63.4 M
Slightly volatile
Capital Stock3.3 K5.8 K2.6 K
Slightly volatile
Non Current Liabilities Other15.2 M14.5 M4.7 M
Slightly volatile
Net Working Capital107.4 M112.6 M55.9 M
Slightly volatile
Short Term Debt2.6 M1.8 M1.4 M
Slightly volatile
Common Stock3.3 K5.8 K2.6 K
Slightly volatile
Property Plant Equipment8.8 M10.3 M5.9 M
Slightly volatile
Deferred Long Term Liabilities124 K139.5 K152.3 K
Slightly volatile
Capital Surpluse459.1 M493.4 M418.1 M
Slightly volatile
Current Deferred Revenue775.5 K816.3 K5.2 M
Slightly volatile
Net Receivables1.2 M1.2 M5.6 M
Slightly volatile
Inventory1.61.81.9647
Slightly volatile
Long Term Debt23.5 M23.5 M31.2 M
Slightly volatile
Short and Long Term Debt5.3 M6 M6.5 M
Slightly volatile

Werewolf Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M2.1 M795.1 K
Slightly volatile
Interest Expense5.6 M5.4 M1.4 M
Slightly volatile
Selling General Administrative14.8 M21.9 M8.8 M
Slightly volatile
Other Operating Expenses53.3 M86.8 M30.6 M
Slightly volatile
Research Development38.5 M64.9 M21.8 M
Slightly volatile
Cost Of Revenue1.5 M2.1 M929.1 K
Slightly volatile
Total Operating Expenses52.5 M84.7 M30.2 M
Slightly volatile
Reconciled Depreciation2.2 M2.1 M560.7 K
Slightly volatile
Interest Income8.1 M7.7 M1.7 M
Slightly volatile
Preferred Stock And Other Adjustments121.6 M136.7 M149.3 M
Slightly volatile
Non Operating Income Net Other1.3 M2.6 M697.7 K
Slightly volatile
Selling And Marketing Expenses2.4 M1.6 M3.6 M
Slightly volatile

Werewolf Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.4 M10.1 M2.9 M
Slightly volatile
Begin Period Cash Flow103 M178.9 M52.8 M
Slightly volatile
Depreciation2.2 M2.1 M563.2 K
Slightly volatile
Capital Expenditures277.5 K292.1 K524.8 K
Pretty Stable
Issuance Of Capital Stock37.1 M21.2 M31.5 M
Pretty Stable
Total Cash From Financing Activities11.2 M11.8 M31.3 M
Pretty Stable
End Period Cash Flow122.5 M129 M63.7 M
Slightly volatile
Change To Liabilities3.7 M3.5 M1.1 M
Slightly volatile
Sale Purchase Of Stock13.7 M14.4 M81.7 M
Slightly volatile
Change To Inventory5.5 M6.2 M6.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.1530.628.8584
Slightly volatile
PTB Ratio0.951.028.4449
Slightly volatile
Days Sales Outstanding26.9928.41124
Slightly volatile
Book Value Per Share2.771.521.6556
Slightly volatile
Average Payables942.4 K1.4 M1 M
Slightly volatile
Stock Based Compensation To Revenue4.424.211.1517
Slightly volatile
Capex To Depreciation0.150.166.8586
Slightly volatile
PB Ratio0.951.028.4449
Slightly volatile
Payables Turnover0.870.540.9126
Slightly volatile
Sales General And Administrative To Revenue9.559.092.5538
Slightly volatile
Research And Ddevelopement To Revenue28.2926.947.6398
Slightly volatile
Capex To Revenue0.140.150.1956
Slightly volatile
Cash Per Share3.12.312.0135
Slightly volatile
Days Payables Outstanding327550446
Slightly volatile
Income Quality1.00.920.9265
Pretty Stable
Net Debt To EBITDA1.261.331.962
Pretty Stable
Current Ratio11.088.579.3884
Very volatile
Tangible Book Value Per Share2.771.521.6556
Slightly volatile
Receivables Turnover6.8613.34.7342
Slightly volatile
Shareholders Equity Per Share2.771.521.6556
Slightly volatile
Debt To Equity0.480.450.3155
Pretty Stable
Capex Per Share0.0050.00530.0178
Pretty Stable
Graham Net Net1.451.521.2841
Slightly volatile
Revenue Per Share0.04750.050.4757
Slightly volatile
Interest Debt Per Share0.540.870.3875
Slightly volatile
Debt To Assets0.280.260.1636
Slightly volatile
Operating Cycle26.9928.41124
Slightly volatile
Price Book Value Ratio0.951.028.4449
Slightly volatile
Days Of Payables Outstanding327550446
Slightly volatile
Ebt Per Ebit0.740.860.9661
Slightly volatile
Company Equity Multiplier1.661.991.9238
Slightly volatile
Long Term Debt To Capitalization0.190.240.2274
Very volatile
Total Debt To Capitalization0.150.30.2213
Pretty Stable
Debt Equity Ratio0.480.450.3155
Pretty Stable
Quick Ratio11.088.579.3884
Very volatile
Net Income Per E B T1.131.141.0565
Pretty Stable
Cash Ratio10.858.419.2491
Very volatile
Days Of Sales Outstanding26.9928.41124
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.0428
Slightly volatile
Price To Book Ratio0.951.028.4449
Slightly volatile
Fixed Asset Turnover0.170.180.8273
Slightly volatile
Debt Ratio0.280.260.1636
Slightly volatile
Price Sales Ratio32.1530.628.8584
Slightly volatile
Asset Turnover0.01620.01710.0878
Slightly volatile
Gross Profit Margin0.04110.04330.7085
Slightly volatile
Price Fair Value0.951.028.4449
Slightly volatile

Werewolf Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap70.1 M73.8 M325.9 M
Slightly volatile

Werewolf Fundamental Market Drivers

Werewolf Upcoming Events

28th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
28th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Werewolf Therapeutics Financial Statements

Werewolf Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Werewolf Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue816.3 K775.5 K
Total Revenue2.2 M2.1 M
Cost Of Revenue2.1 M1.5 M
Stock Based Compensation To Revenue 4.21  4.42 
Sales General And Administrative To Revenue 9.09  9.55 
Research And Ddevelopement To Revenue 26.94  28.29 
Capex To Revenue 0.15  0.14 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(44.90)(42.65)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
How To Invest In Werewolf
Details
Is Werewolf Stock a good investment?
Details
What is Werewolf Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Werewolf Therapeutics Correlation against competitors.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. Market participants price Werewolf higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Werewolf Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(1.57)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.41)
Return On Equity
(1.22)
Investors evaluate Werewolf Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Werewolf Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Werewolf Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Werewolf Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY